$8.11 Million in Sales Expected for Concert Pharmaceuticals Inc (CNCE) This Quarter

Analysts expect that Concert Pharmaceuticals Inc (NASDAQ:CNCE) will announce sales of $8.11 million for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Concert Pharmaceuticals’ earnings, with estimates ranging from $20,000.00 to $16.19 million. Concert Pharmaceuticals posted sales of $20,000.00 in the same quarter last year, which suggests a positive year-over-year growth rate of 40,450%. The company is scheduled to issue its next earnings results on Monday, March 5th.

On average, analysts expect that Concert Pharmaceuticals will report full-year sales of $8.11 million for the current fiscal year, with estimates ranging from $144.07 million to $160.07 million. For the next financial year, analysts forecast that the company will report sales of $250,000.00 per share. Zacks’ sales averages are an average based on a survey of sell-side research firms that follow Concert Pharmaceuticals.

Concert Pharmaceuticals (NASDAQ:CNCE) last announced its earnings results on Thursday, November 9th. The biotechnology company reported ($0.70) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.54) by ($0.16). Concert Pharmaceuticals had a negative return on equity of 51.48% and a net margin of 62.31%.

A number of analysts have recently issued reports on CNCE shares. Stifel Nicolaus reaffirmed a “buy” rating and set a $30.00 target price on shares of Concert Pharmaceuticals in a research report on Sunday, October 22nd. BidaskClub lowered Concert Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Friday, December 22nd. Zacks Investment Research lowered Concert Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, October 10th. HC Wainwright reaffirmed a “buy” rating and set a $21.00 target price on shares of Concert Pharmaceuticals in a research report on Friday, November 10th. Finally, Mizuho started coverage on Concert Pharmaceuticals in a research report on Thursday, October 26th. They set a “buy” rating and a $23.00 target price on the stock. One research analyst has rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $24.33.

In related news, Director Ronald W. Barrett sold 14,156 shares of the business’s stock in a transaction dated Monday, December 4th. The stock was sold at an average price of $24.70, for a total value of $349,653.20. Following the completion of the sale, the director now directly owns 3,539 shares of the company’s stock, valued at $87,413.30. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Richard Aldrich sold 31,236 shares of the business’s stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $19.14, for a total value of $597,857.04. Following the completion of the sale, the director now directly owns 286,975 shares of the company’s stock, valued at $5,492,701.50. The disclosure for this sale can be found here. Over the last three months, insiders sold 1,358,248 shares of company stock valued at $35,716,123. 10.10% of the stock is owned by corporate insiders.

A number of institutional investors have recently made changes to their positions in CNCE. Citadel Advisors LLC bought a new stake in Concert Pharmaceuticals in the second quarter valued at about $6,634,000. Lyon Street Capital LLC boosted its stake in Concert Pharmaceuticals by 405.5% in the second quarter. Lyon Street Capital LLC now owns 434,752 shares of the biotechnology company’s stock valued at $6,065,000 after acquiring an additional 348,741 shares during the period. Acadian Asset Management LLC acquired a new position in Concert Pharmaceuticals in the fourth quarter valued at approximately $7,713,000. Senvest Management LLC boosted its stake in Concert Pharmaceuticals by 458.8% in the third quarter. Senvest Management LLC now owns 314,629 shares of the biotechnology company’s stock valued at $4,641,000 after acquiring an additional 258,329 shares during the period. Finally, Ingalls & Snyder LLC boosted its stake in Concert Pharmaceuticals by 14.5% in the third quarter. Ingalls & Snyder LLC now owns 1,209,062 shares of the biotechnology company’s stock valued at $17,834,000 after acquiring an additional 153,062 shares during the period. 65.35% of the stock is owned by hedge funds and other institutional investors.

Shares of Concert Pharmaceuticals (NASDAQ:CNCE) traded up $0.10 during midday trading on Tuesday, hitting $19.71. The stock had a trading volume of 697,400 shares, compared to its average volume of 724,464. Concert Pharmaceuticals has a twelve month low of $8.61 and a twelve month high of $30.71. The stock has a market capitalization of $446.57, a price-to-earnings ratio of 5.30 and a beta of 1.67.

ILLEGAL ACTIVITY NOTICE: “$8.11 Million in Sales Expected for Concert Pharmaceuticals Inc (CNCE) This Quarter” was published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright laws. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/01/23/8-11-million-in-sales-expected-for-concert-pharmaceuticals-inc-cnce-this-quarter.html.

Concert Pharmaceuticals Company Profile

Concert Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company’s deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas.

Get a free copy of the Zacks research report on Concert Pharmaceuticals (CNCE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Concert Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply